Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 August 2025 | Story Tshepo Tsotetsi | Photo Tshepo Tsotetsi
EMS Womens Function
From the left: Prof Brownhilder Neneh, Vice-Dean of the Faculty of Economic and Management Sciences; Prof Hester C. Klopper, Vice-Chancellor and Principal of the UFS; Simone Williams, Faculty Manager; and Dr Celeste Campher, Senior Lecturer in the Faculty of Economic and Management Sciences, at the Women’s Function held on the Bloemfontein Campus on 18 August.

The University of the Free State’s (UFS) Faculty of Economic and Management Sciences recently hosted a Women’s Function on the UFS Bloemfontein Campus – an event that paid tribute to women’s leadership in academia during Women’s Month. The gathering, held on 18 August 2025, was marked by a historic conversation with Prof Hester C. Klopper, UFS Vice-Chancellor and Principal, who earlier this year became the first woman to lead the university in its 121-year history.

The function brought together women academics and professional staff in an atmosphere of connection and reflection to converse on breaking barriers, building futures, and empowering women in higher education. In conversation with colleagues, Prof Klopper shared her personal journey in higher education, her leadership philosophy, and the values that have guided her career. The occasion created a meaningful platform for colleagues to reflect on the role of women in shaping the future of the faculty and the university.

 

Breaking barriers, building futures

Prof Klopper described her appointment as both humbling and historic: “It is an extraordinary honour to be entrusted with this responsibility. This milestone is not just a personal achievement, but also a reflection of the progress we have made as a university and as a society in recognising and valuing diversity in leadership. I stand on the shoulders of many trailblazers who paved the way, and I hope my appointment inspires women to believe that there are no limits to what they can achieve.”

She shared pivotal moments across her career journey – from transitioning into academia to international leadership experiences that shaped her vision. “You become aware of a growing, burning desire to plough back what you have learned; to pay forward in some way after receiving so many opportunities for growth, so much exposure to great role models, and such incredible learning experiences,” she said.

Acknowledging the challenges women still face in higher education, Prof Klopper reflected: “Academia has traditionally been male-dominated. In order to overcome stereotyping and bias, I drew on the values instilled by my parents – hard work, believing in yourself, non-discrimination, fairness, and care. These have been incredibly valuable in my journey.” She also highlighted the importance of supportive partnerships when balancing professional and family responsibilities.

Prof Brownhilder Neneh, Vice-Dean: Research, Engagement and Internationalisation in the Faculty, said these reflections captured the very purpose of the gathering. “With Prof Klopper serving as the first female Vice-Chancellor and Principal of the UFS, it was important to create a platform for her to inspire and empower women academics,” she said. “By sharing her career journey and insights, she demonstrated how barriers can be overcome in higher education leadership.” 

She added that the conversation reinforced an important message: “Women, too, can achieve whatever they aspire to become. Prof Klopper reminded us that one must be clear about the message they want to communicate, know what they stand for, and remain consistent, authentic and honest. She emphasised the importance of always considering what you bring to the table – your expertise and knowledge – which ultimately opens doors. She also reminded us that women need to create their own values and live them, be intentional, and show up. There is no single recipe – each person must find their own rhythm and pursue it deliberately.”

Prof Klopper echoed with a message of encouragement to young women: “Have the courage to embrace your own authentic leadership style. Do not allow others to define who you are – believe in your own abilities. Knowledge without action is incomplete. Lead with heart, take intellectual risks, and remember that talent exists everywhere, but you have the power to create opportunity.”

Prof Neneh added that the event was not only a celebration but also a call to action: “Women play a vital role in enriching the academic project by bringing diverse experiences, perspectives, and leadership approaches. I hope colleagues left encouraged to pursue their aspirations with confidence and inspired to embrace mentorship, sponsorship, and solidarity among women academics.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept